Filing Flows › 10x Genomics (TXG) › Guidance & outlook
10x Genomics (TXG) guidance and outlook
10x Genomics (TXG) raised its guidance on Nov 5, 2026: Revenue $625M–$635M for FY2026. 10x Genomics' 10-Q filed Nov 6, 2026 makes 10 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $625M–$635M | raised |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 6, 2026
- We expect the acquisition will allow us to expand our proteomics capabilities.
- Excluding non-recurring license and royalty revenue related to patent litigation settlements in 2026 and 2025, we expect our revenues to increase in 2026 as compared to 2025.
- We expect our gross margin to decrease in the fourth quarter of 2026 compared to the prior quarter primarily due to changes in product mix.
- Excluding gains on settlements recorded in 2026 and 2025, we expect our operating expenses to modestly decrease in 2026 compared to the prior year as a result of our ongoing efforts to manage our spend.
- We expect other income (expense), net, to fluctuate, potentially significantly, from quarter to quarter due to potential changes in the fair value of contingent consideration and fluctuations in foreign currency exchange rates.
- We currently anticipate making aggregate capital expenditures of between approximately $10 million and $15 million during the next 12 months, which we expect to include, among other expenditures, equipment to be used for manufacturing and research and development.
- We expect to continue to incur operating losses for the foreseeable future.
- However, our liquidity assumptions may prove to be incorrect, and we could exhaust our available financial resources sooner than we currently expect.
- We intend to continue to evaluate market conditions and may in the future pursue additional sources of funding, such as mortgage or other financing, to further enhance our financial position and to execute our business strategy.
- Critical accounting estimates are those estimates made in accordance with United States generally accepted accounting principles (“GAAP”) that involve a significant level of judgments and estimates that can affect the results of operations and financial position of the Company.
10x Genomics' latest quarter
10x Genomics, Q3 2026: revenue $151M (+1% year over year), operating margin -10.7%, net loss $19.4M, operating cash flow $15.8M. The chart follows the revenue to costs, profit and cash.
Questions
Did 10x Genomics raise or lower its guidance?
10x Genomics (TXG) raised its guidance on Nov 5, 2026: Revenue $625M–$635M for FY2026.
What does 10x Genomics expect?
We expect the acquisition will allow us to expand our proteomics capabilities. Excluding non-recurring license and royalty revenue related to patent litigation settlements in 2026 and 2025, we expect our revenues to increase in 2026 as compared to 2025. We expect our gross margin to decrease in the fourth quarter of 2026 compared to the prior quarter primarily due to changes in product mix.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.